CLDX (STOCKS)
Celldex Therapeutics, Inc
$32.590000
+0.350000 (+1.09%)
Prev close: $32.240000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Anthony S. Marucci
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,505.77M
- Employees
- 186
- P/E (TTM)
- -8.28
- P/B (TTM)
- 4.07
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
12
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.22 | $-1.03 | -0.1912 | -18.58% |
|
Sep 2025 (Q3)
|
$-1.01 | $-0.92 | -0.0913 | -9.94% |
|
Jun 2025 (Q2)
|
$-0.85 | $-0.87 | +0.0229 | +2.62% |
|
Mar 2025 (Q1)
|
$-0.81 | $-0.77 | -0.0399 | -5.18% |
Financial Statements
| Revenues | $1.55M |
| Benefits Costs and Expenses | $260.30M |
| Cost Of Revenue | $200.00K |
| Costs And Expenses | $288.91M |
| Gross Profit | $1.35M |
| Operating Expenses | $288.71M |
| Research and Development | $245.07M |
| Other Operating Expenses | $43.64M |
| Operating Income/Loss | -$287.37M |
| Income/Loss From Continuing Operations After Tax | -$258.76M |
| Income/Loss From Continuing Operations Before Tax | -$258.76M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$258.76M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$258.76M |
| Net Income/Loss Available To Common Stockholders, Basic | -$258.76M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.90 |
| Diluted Earnings Per Share | -$3.90 |
| Basic Average Shares | 66,422,000 |
| Diluted Average Shares | 66,422,000 |
| Assets | $582.98M |
| Current Assets | $534.66M |
| Noncurrent Assets | $48.32M |
| Fixed Assets | $5.33M |
| Intangible Assets | $27.19M |
| Non-current Prepaid Expenses | $12.80M |
| Other Non-current Assets | $3.00M |
| Liabilities | $55.82M |
| Current Liabilities | $50.99M |
| Accounts Payable | $1.18M |
| Wages | $11.81M |
| Other Current Liabilities | $38.00M |
| Noncurrent Liabilities | $4.83M |
| Equity | $527.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $527.17M |
| Liabilities And Equity | $582.98M |
| Net Cash Flow From Operating Activities | -$210.95M |
| Net Cash Flow From Operating Activities, Continuing | -$210.95M |
| Net Cash Flow From Investing Activities | $209.07M |
| Net Cash Flow From Investing Activities, Continuing | $209.07M |
| Net Cash Flow From Financing Activities | $2.39M |
| Net Cash Flow From Financing Activities, Continuing | $2.39M |
| Net Cash Flow | $515.00K |
| Net Cash Flow, Continuing | $515.00K |
| Comprehensive Income/Loss | -$258.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$258.45M |
| Other Comprehensive Income/Loss | -$258.45M |